Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

• Ngā kaituhi matua: Sabrina Rossi (Author), Alessandra Cassano (Author), Antonia Strippoli (Author), Giovanni Schinzari (Author), Ettore D'Argento (Author), Michele Basso (Author), Carlo Barone (Author)
• Hōputu: Pukapuka
• I whakaputaina: BioExcel Publishing Ltd, 2017-11-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Background: Eribulin mesylate is currently approved in the United States and Europe for the treatment of metastatic breast cancer (MBC). Scope: The objective of this retrospective study is to find specific predictive criteria related to patient or tumor characteristics in order to select pa...